CONNECT WITH US
HealthTech

HealthTech

WHO approves clinical trials on two new Ebola vaccines

Medical Xpress logo

Published on

Add as a preferred source on Google
WHO approves clinical trials on two new Ebola vaccines

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

The World Health Organization on Wednesday approved clinical trials for two new Ebola vaccines, as doctors fight to control an outbreak in Africa that has killed more than 5,300 people.

"Last month, a vaccine trial began using the Ervebo vaccine, which is approved for Ebola virus, but not for Bundibugyo virus" ravaging the Democratic Republic of Congo, WHO chief Tedros Adhanom Ghebreyesus told reporters.

"Today, WHO expert groups are recommending adding two vaccine candidates to the trial," he added.

Those two—ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469—were developed specifically for the Bundibugyo virus, he explained.

The DRC's National Institute for Biomedical Research is leading the trial, backed by partners including WHO, said Tedros.

"Vaccines are powerful tools, but they are not substitutes for the proven measures that can save lives now: early care, contact tracing, isolation, safe and dignified burials and trusted engagement with communities," he added.

On Monday, the Africa Centres for Disease Control and Prevention (Africa CDC) said Africa's ongoing Ebola epidemic had killed more than 5,300 people, the vast majority of them in the Democratic Republic of Congo.

A total of 10,444 cases have been confirmed, with a fatality rate of more than 50%, it added.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.